Literature DB >> 23399526

Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria.

Jan Tack1, Nicholas J Talley.   

Abstract

Dyspepsia refers to a heterogeneous group of symptoms that are localized in the epigastric region. Typical dyspeptic symptoms include postprandial fullness, early satiation, epigastric pain and epigastric burning, but other upper gastrointestinal symptoms such as nausea, belching or abdominal bloating often occur. Functional dyspepsia is defined as the presence of dyspeptic symptoms in the absence of an organic cause that readily explains them. The Rome III consensus proposed the subdivision of functional dyspepsia into postprandial distress syndrome (PDS), characterized by postprandial fullness and early satiation, and epigastric pain syndrome (EPS), characterized by epigastric pain or burning. Epidemiological studies in the USA and Europe confirmed the presence of both subgroups, with good separation between EPS and PDS. By contrast, other studies have found major overlap between EPS and PDS in patients with functional dyspepsia in specialist care centres in Europe and Asia. Preliminary pathophysiological studies suggest that PDS might be characterized by a higher prevalence of impaired gastric accommodation than EPS and raised duodenal eosinophil counts. Whether different treatment approaches are needed for EPS and PDS is currently unclear; only acotiamide, a new drug for the treatment of functional dyspepsia, has been found to be efficacious in PDS but not in EPS. Further randomized controlled trials testing treatment response by subgroup are urgently needed.

Entities:  

Mesh:

Year:  2013        PMID: 23399526     DOI: 10.1038/nrgastro.2013.14

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  54 in total

1.  Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease.

Authors:  Tomotaka Shindo; Seiji Futagami; Tetsuro Hiratsuka; Akane Horie; Tatsuhiko Hamamoto; Nobue Ueki; Masafumi Kusunoki; Kazumasa Miyake; Katya Gudis; Taku Tsukui; Katsuhiko Iwakiri; Choitsu Sakamoto
Journal:  Digestion       Date:  2009-02-27       Impact factor: 3.216

2.  High frequency of overlap between functional dyspepsia and overactive bladder.

Authors:  J Matsuzaki; H Suzuki; Y Fukushima; K Hirata; S Fukuhara; S Okada; T Hibi
Journal:  Neurogastroenterol Motil       Date:  2012-05-23       Impact factor: 3.598

3.  Classification of functional dyspepsia based on concomitant bowel symptoms.

Authors:  J Matsuzaki; H Suzuki; K Asakura; Y Fukushima; J M Inadomi; T Takebayashi; T Hibi
Journal:  Neurogastroenterol Motil       Date:  2012-01-11       Impact factor: 3.598

Review 4.  Functional gastroduodenal disorders.

Authors:  Jan Tack; Nicholas J Talley; Michael Camilleri; Gerald Holtmann; Pinjin Hu; Juan-R Malagelada; Vincenzo Stanghellini
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

5.  The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.

Authors:  R Carlsson; J Dent; E Bolling-Sternevald; F Johnsson; O Junghard; K Lauritsen; S Riley; L Lundell
Journal:  Scand J Gastroenterol       Date:  1998-10       Impact factor: 2.423

6.  Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.

Authors:  S Futagami; M Shimpuku; J M Song; Y Kodaka; H Yamawaki; H Nagoya; T Shindo; T Kawagoe; A Horie; K Gudis; K Iwakiri; C Sakamoto
Journal:  Digestion       Date:  2012-07-27       Impact factor: 3.216

7.  Prevalence of functional dyspepsia and its subgroups in patients with eating disorders.

Authors:  Antonella Santonicola; Monica Siniscalchi; Pietro Capone; Serena Gallotta; Carolina Ciacci; Paola Iovino
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

8.  Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia?

Authors:  S Haag; W Senf; S Tagay; G Heuft; G Gerken; N J Talley; G Holtmann
Journal:  Neurogastroenterol Motil       Date:  2009-10-08       Impact factor: 3.598

9.  Rome III subgroups of functional dyspepsia exhibit different characteristics of antral contractions measured by strain rate imaging - a pilot study.

Authors:  A B Ahmed; K Matre; T Hausken; H Gregersen; O H Gilja
Journal:  Ultraschall Med       Date:  2012-12-17       Impact factor: 6.548

10.  The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria.

Authors:  Anjiang Wang; XianHua Liao; LiShou Xiong; Sui Peng; YingLian Xiao; SiChun Liu; PinJin Hu; MinHu Chen
Journal:  BMC Gastroenterol       Date:  2008-09-23       Impact factor: 3.067

View more
  84 in total

1.  Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options.

Authors:  Kimberly N Harer; William L Hasler
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-02

2.  Acotiamide: first global approval.

Authors:  Mary L Nowlan; Mary L Nolan; Lesley J Scott
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

3.  Specific dyspeptic symptoms are associated with poor response to therapy in patients with gastroesophageal reflux disease.

Authors:  A D'Alessandro; F P Zito; M Pesce; P Andreozzi; E Efficie; M Cargiolli; F Maione; G D De Palma; R Cuomo; G Sarnelli
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

4.  Cerebral mechanism of puncturing at He-Mu point combination for functional dyspepsia: study protocol for a randomized controlled parallel trial.

Authors:  Shuai Yin; Yuan Chen; Du Lei; Rui-Rui Sun; Ting-Ting Ma; Pei-Min Feng; Zhao-Xuan He; Xue-Ling Suo; Pei-Hong Ma; Yu-Zhu Qu; Ke Qiu; Miao-Miao Jing; Qi-Yong Gong; Fan-Rong Liang; Jiao Chen; Fang Zeng
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

5.  A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.

Authors:  Kumiko Nakamura; Toshihiko Tomita; Tadayuki Oshima; Haruki Asano; Takahisa Yamasaki; Takuya Okugawa; Takashi Kondo; Tomoaki Kono; Katsuyuki Tozawa; Yoshio Ohda; Hirokazu Fukui; Fukushima Kazuhito; Shozo Hirota; Jiro Watari; Hiroto Miwa
Journal:  J Gastroenterol       Date:  2016-09-17       Impact factor: 7.527

6.  Hypnotherapy for Esophageal Disorders.

Authors:  Megan E Riehl; Laurie Keefer
Journal:  Am J Clin Hypn       Date:  2015-07

7.  Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.

Authors:  Nicholas J Talley; G Richard Locke; Yuri A Saito; Ann E Almazar; Ernest P Bouras; Colin W Howden; Brian E Lacy; John K DiBaise; Charlene M Prather; Bincy P Abraham; Hashem B El-Serag; Paul Moayyedi; Linda M Herrick; Lawrence A Szarka; Michael Camilleri; Frank A Hamilton; Cathy D Schleck; Katherine E Tilkes; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

Review 8.  Current management strategies and emerging treatments for functional dyspepsia.

Authors:  Michael Camilleri; Vincenzo Stanghellini
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-05       Impact factor: 46.802

Review 9.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

10.  Caecal pH is a biomarker of excessive colonic fermentation.

Authors:  Adam D Farmer; Sahar D Mohammed; George E Dukes; S Mark Scott; Anthony R Hobson
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.